peptidylprolyl isomerase A pseudogene 64Genealiases: []
Q-omics provides the consensus-scored PPIAP64 profile across patient tissues and cancer cell-line models. PPIAP64 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PPIAP64 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PPIAP64 RNA expression shows 11,121 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, COAD, and GBM as cancer lineages where PPIAP64 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP64 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP64 survival associations across molecular data types. PPIAP64 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP64 RNA expression–survival associations across cancer types. High PPIAP64 expression shows unfavorable associations in STAD and UVM, but favorable associations in KIRP, UCS, CESC and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PPIAP64 RNA expression.
This table summarizes PPIAP64 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP64. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP64 shows lower tumor expression in UCEC and THCA and higher tumor expression in COAD, LUAD, BRCA and KIRP. The COAD box plot shows higher PPIAP64 RNA expression in tumor versus normal tissue (log2 FC = +0.252, t-test p = .009).
This table shows molecular features associated with PPIAP64 in patient tissues and cancer cell lines. In patient samples, PPIAP64 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
